Lipotek is dedicated to the development of novel adjuvants based on its Lipovaxin and Lipokel nanoparticle technologies.
There has been increased interest in adjuvant technologies, in part driven by concerns associated with the likelihood of strain drift, emerging infectious diseases, the need to potentiate poor immunogens with safe adjuvants.
Novel adjuvants are potentially important for “vaccine resistant” or “host response deficient” global health challenges including HIV, TB, malaria.
Potential benefits of adjuvants include:
- To enhance the rapidity and/or intensity of immune responses
- To enhance the “breadth” of response for cross-protective and T cell mediated effects (protect against pathogen evolution)
- To enhance the duration of response and/or ability to prime for later response (memory)
Our preferred approach is to use the synthetic delivery modules Lipovaxin and Lipokel to facilitate dendritic cell targeting and activation, antigen processing and cross presentation in vitro and in vivo.